A Titrated Morphine Analgesic Regimen Comparing Substance Users and Non-Users with AIDS-Related Pain Ronald Kaplan, MD, Joseph Slywka, PhD, Susan Slagle,

Slides:

Advertisements

Similar presentations

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Advertisements

The Treatment of Chronic Cancer Pain in a Cancer Hospital in the Netherlands Rianne de Wit, MS, Frits van Dam, PhD, Ans Vielvoye-Kerkmeer, PhD, Carlien.

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Factors to Inform Clinicians About the End of Life in Severe Chronic Obstructive Pulmonary Disease Roberto Benzo, MD, MS, Wendy Siemion, MD, Paul Novotny,

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Clinical Trial Results with OROS® Hydromorphone

Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized,

Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients Tatsuya Morita, MD, Junichi Tsunoda, MD, Satoshi Inoue, MD,

An Effective Treatment of Severe Complex Regional Pain Syndrome Type 1 in a Child Using High Doses of Intrathecal Ziconotide Michael Stanton-Hicks, MD,

The Impact of Chronic Pain on Life in the Household

Optimization of opioid therapy for preventing incident pain associated with bone metastases Sebastiano Mercadante, MD, Patrizia Villari, MD, Patrizia.

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain Jacques R. Caldwell, MD, Ronald J. Rapoport,

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine Rainer Sabatowski, MD, Stefan.

The adequacy of the minimum data set assessment of pain in cognitively impaired nursing home residents Jiska Cohen-Mansfield, PhD, ABPP Journal of Pain.

Samy A. Alsirafy, MBBCh, MSc, MD, ABHPM, Dip Pall Med

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Bettina N. Nielsen, MSc, Gitte Aagaard, RN, Steen W

NMDA-Receptor Antagonists in Neuropathic Pain

Symptomatic Therapy of Dyspnea with Strong Opioids and Its Effect on Ventilation in Palliative Care Patients Katri Elina Clemens, MD, PhD, Eberhard Klaschik,

Antiemetic and analgesic-sparing effects of diphenhydramine added to morphine intravenous patient-controlled analgesia T.-F. Lin, Y.-C. Yeh, Y.-H. Yen,

Eduardo Bruera, MD, Raul Sala, MD, Odette Spruyt, MD, J

Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: An open-label prospective clinical trial

Inpatient Palliative Care and Patient Pain: Pre- and Post-Outcomes

An Open-Label, Multi-Dose Efficacy and Safety Study of Intramuscular Tetrodotoxin in Patients with Severe Cancer-Related Pain Neil A. Hagen, MD, FRCPC,

Advances in Rheumatology

Factors to Inform Clinicians About the End of Life in Severe Chronic Obstructive Pulmonary Disease Roberto Benzo, MD, MS, Wendy Siemion, MD, Paul Novotny,

Samuel J Hassenbusch, MD, PhD, Russell K Portenoy, MD

Transdermal Fentanyl for Chronic Pain in AIDS

Treatment of chronic autoimmune urticaria with omalizumab

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and.

Nancy E. Avis, PhD, Beverly Levine, PhD, Sarah A

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

Suresh K Joishy, MD, FACP, Declan Walsh, MSc, FACP

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

Cancer patients' share in a population's Use of opioids

The Role of Patients' Expectations in the Development of Anticipatory Nausea Related to Chemotherapy for Cancer Jane T. Hickok, MD, MPH, Joseph A. Roscoe,

The Role of a Low-Dose Ketamine-Midazolam Regimen in the Management of Severe Painful Crisis in Patients With Sickle Cell Disease Qutaiba A. Tawfic,

Susan C. Miller, PhD, Dan K. Kiely, MPH, MA, Joan M

NMDA-Receptor Antagonists and Opioid Receptor Interactions as Related to Analgesia and Tolerance Donald D Price, PhD, David J Mayer, PhD, Jianren Mao,

Strategies in Pain Management

Dose-response relationship between opioid use and adverse effects after ambulatory surgery Sean Z Zhao, PhD, MD, Frances Chung, MD, David B Hanna, MS,

Methadone Analgesia in Cancer Pain Patients on Chronic Methadone Maintenance Therapy Paolo L Manfredi, MD, Gilbert R Gonzales, Andrea L Cheville, Craig.

Improving Access to Opioid Analgesics for Palliative Care in India

The COX-2 Specific Inhibitor, Valdecoxib, Is An Effective, Opioid-Sparing Analgesic in Patients Undergoing Total Knee Arthroplasty Lowell W Reynolds,

The Assessment of Cancer Pain in North India

Proglumide as a Morphine Adjunct in Cancer Pain Management

J. Lillesø, N.A. Hammer, J.L. Pedersen, H. Kehlet

Gertrud Andersen, MD, Lona Christrup, PhD, Per Sjøgren, MD

Hsiu-Ying Huang, PhD, RN, AOCN, Diana J Wilkie, PhD, RN, FAAN, C

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

The Impact of Combined Use of Opioids, Antipsychotics, and Anxiolytics on Survival in the Hospice Setting Marin Golčić, MD, Renata Dobrila-Dintinjana,

Evaluating the Quality of Dying and Death

The Impact of Delirium on the Circadian Distribution of Breakthrough Analgesia in Advanced Cancer Patients Bruno Gagnon, MD, Peter G. Lawlor, MB, Isabelle.

Clinical and Economic Impact of Palliative Care Consultation

A Strategy for Conversion From Subcutaneous to Oral Ketamine in Cancer Pain Patients: Effect of a 1:1 Ratio Miguel Angel Benítez-Rosario, MD, PhD, Antonio.

Knowledge and Attitudes of Italian Medical Staff Towards the Approach and Treatment of Patients in Pain Marco Visentin, MD, Leonardo Trentin, MD, Roberto.

Clinical Economics Journal of Pain and Symptom Management

Goal Communication in Palliative Care Decision-Making Consultations

Physical Function in Patients with Cancer

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza™, and a Twice-Daily Controlled-Release Morphine.

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Assessment of Pain Experiences after Elective Surgery

Economic Evaluation of the Fentanyl Transdermal System for the Treatment of Chronic Moderate to Severe Pain Deirdre M Neighbors, BA, Timothy J Bell,

Depomedroxyprogesterone Acetate for Hot Flashes

Nausea and Vomiting Remain a Significant Clinical Problem

Supraclavicular reoperation for neurogenic thoracic outlet syndrome

Presentation transcript:

A Titrated Morphine Analgesic Regimen Comparing Substance Users and Non-Users with AIDS-Related Pain Ronald Kaplan, MD, Joseph Slywka, PhD, Susan Slagle, MPH, Kristen Ries, MD Journal of Pain and Symptom Management Volume 19, Issue 4, Pages 265-273 (April 2000) DOI: 10.1016/S0885-3924(00)00117-2

Fig. 1 Mean daily pain intensity for baseline and end of study. *Statistically significant reduction in pain (P ≤ 0.0001). No significant differences were found between DU and NU. Pain intensity: 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = overwhelming Journal of Pain and Symptom Management 2000 19, 265-273DOI: (10.1016/S0885-3924(00)00117-2)

Fig. 2 Total daily morphine requirements (intent-to-treat patients). #Significant interaction (P = 0.0004). DU and NU had significant increase in dose (P ≤ 0.0006). DU were significantly higher than NU during the final 3 days (P = 0.0018). *Significant reduction in IRM (P = 0.0100). Significant difference between DU and NU (P = 0.0006). @Significant interaction (P = 0.0055). DU required more morphine both initial (P = 0.0436) and final (P = 0.0004); DU showed significant increase over time (P = 0.040) Journal of Pain and Symptom Management 2000 19, 265-273DOI: (10.1016/S0885-3924(00)00117-2)